GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ValiRx PLC (LSE:VAL) » Definitions » Other Current Assets

ValiRx (LSE:VAL) Other Current Assets

: £0.28 Mil (As of Jun. 2023)
View and export this data going back to 2000. Start your Free Trial

ValiRx's other current assets for the quarter that ended in Jun. 2023 was £0.28 Mil.

ValiRx's quarterly other current assets increased from Jun. 2022 (£0.20 Mil) to Dec. 2022 (£0.25 Mil) and increased from Dec. 2022 (£0.25 Mil) to Jun. 2023 (£0.28Mil).

ValiRx's annual other current assets increased from Dec. 2020 (£0.08 Mil) to Dec. 2021 (£0.14 Mil) increased from Dec. 2021 (£0.14 Mil) to Dec. 2022 (£0.25 Mil).


ValiRx Other Current Assets Historical Data

The historical data trend for ValiRx's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ValiRx Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22
Other Current Assets
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.57 0.34 0.08 0.14 0.25

ValiRx Semi-Annual Data
Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23
Other Current Assets Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.03 0.14 0.20 0.25 0.28

ValiRx Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.


ValiRx Other Current Assets Related Terms

Thank you for viewing the detailed overview of ValiRx's Other Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


ValiRx (LSE:VAL) Business Description

Traded in Other Exchanges
Address
4 Barling Way, Eliot Park Innovation Centre, Nuneaton, GBR, CV10 7RH
ValiRx PLC is a UK-based biopharmaceutical company. It mainly engages in developing technologies and products in oncology therapeutics and diagnostics. The area of focus for the company is the treatment of cancer and associated biomarkers, specializing in epigenomic and genetic analysis. The company develops therapeutics across fields in oncology and has a portfolio of products in the pipeline which include GeneICE for Silencing Rebellious Genes, VAL201 for prostate cancer, NAV3 for the cancer screening test, and VAL401 for lung cancer.

ValiRx (LSE:VAL) Headlines

From GuruFocus

Valaris Announces Contract Award for Drillship VALARIS DS-12

By Business Wire Business Wire 11-21-2022

Valaris Provides Fleet Status Report

By Business Wire Business Wire 01-13-2023

Valaris Publishes Sustainability Report

By Business Wire Business Wire 12-15-2022

Valaris Announces Drillship Contract Award

By Business Wire 07-31-2023

Valaris Provides Fleet Status Report

By Business Wire 08-02-2023